BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...
Results: BioNTech SE Confounded Analyst Expectations With A Surprise Profit
Last week, you might have seen that BioNTech SE ( NASDAQ:BNTX ) released its quarterly result to the market. The ...
BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Advancements ...
BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.
Q3 2024 BioNTech SE Earnings Call
Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.
BioNTech Third Quarter 2024 Earnings: Beats Expectations
Third Quarter 2024 Results Key Financial Results Revenue: €1.24b (up 39% from 3Q 2023).
BioNTech’s Q3 2024: Strong Revenue and Oncology Progress
BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...
BioNTech SE Reports Strong Revenue Growth Amid Rising R&D Costs
BioNTech SE (BNTX) has released an update. BioNTech SE’s quarterly report for the period ending September 30, 2024, reveals a ...
Yahoo Finance6d
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, ...
Yahoo Finance6d
BioNTech’s Q3 2024: Strong Revenue and Oncology Progress
BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 billion, largely driven by the successful launch of its variant ...